Home › Entities › academia › A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy

A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy

Research article (Statistical Methods in Medical Research, 2022) · cited 12× · AI/ML
academia openalex:W4212795289
Press Enter · cited answer in seconds

A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy

Summary

A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy is a scholarly article[1].

Key Facts

  • A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy's instance of is recorded as scholarly article[2].

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [2] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy. Retrieved May 24, 2026, from https://4ort.xyz/entity/a-bayesian-phase-i-ii-biomarker-based-design-for-identifying-subgroup-specific-optimal-dose-for-immunotherapy
MLA “A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/a-bayesian-phase-i-ii-biomarker-based-design-for-identifying-subgroup-specific-optimal-dose-for-immunotherapy.
BibTeX @misc{4ortxyz_a-bayesian-phase-i-ii-biomarker-based-design-for-identifying-subgroup-specific-optimal-dose-for-immunotherapy_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy}}, year = {2026}, url = {https://4ort.xyz/entity/a-bayesian-phase-i-ii-biomarker-based-design-for-identifying-subgroup-specific-optimal-dose-for-immunotherapy}, note = {Accessed: 2026-05-24}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy — https://4ort.xyz/entity/a-bayesian-phase-i-ii-biomarker-based-design-for-identifying-subgroup-specific-optimal-dose-for-immunotherapy (retrieved 2026-05-24)

Canonical URL: https://4ort.xyz/entity/a-bayesian-phase-i-ii-biomarker-based-design-for-identifying-subgroup-specific-optimal-dose-for-immunotherapy · Last refreshed: